Manuscript no. HAEMATOL/2012/067983 entitled "Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants"

Authors: Emma M.C. Driessen, Eddy H.J. van Roon, Jill A.P. Spijkers-Hagelstein, Pauline Schneider, Paola de Lorenzo, Maria Grazia Valsecchi, Rob Pieters, and Ronald W. Stam

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:

• Ronald W. Stam, Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands, r.stam@erasmusmc.nl

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): *"Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 …… Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".*

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study: Rob Pieters, Ronald Stam, Emma Driessen

3) Design & Methods. The following authors were responsible for specific investigations:

• Ronald Stam was responsible for supervising all the experiments
• Pauline Schneider was responsible for processing patient material
• Jill Spijkers-Hagelstein was responsible for MTT assays
• Emma Driessen/ Eddy van Roon were responsible for mutation screening
• Emma Driessen was responsible for statistical analysis
• Emma Driessen/Pauline Schneider were responsible DNA/RNA extractions and for cloning experiment
• Emma Driessen was responsible for prednisolone exposure experiment
• Maria Valsecchi/Paola de Lorenzo/Rob Pieters were responsible for collecting clinical data for all patients enrolled in the Interfant trial studies

4) Results. The following authors were responsible for specific portions of the results, including figures and tables:

• Ronald Stam/ Rob Pieters were responsible for reviewing the results
• Emma Driessen/ Eddy van Roon were responsible for analysis of mutation screening
• Emma Driessen was responsible for statistical analysis
• Emma Driessen was responsible for all figures and tables
• Paolo de Lorenzo/ Maria Grazia Valsecchi were responsible for reviewing the statistical analysis
• Paolo de Lorenzo/ Maria Grazia Valsecchi were responsible for collecting the survival data

5) Writing the manuscript. The following authors were responsible for writing the manuscript:

• Emma Driessen/ Ronald Stam were responsible for writing the manuscript
• Ronald Stam/ Rob Pieters were responsible for reviewing and revising the manuscript

6) Contributors Listed in Acknowledgments:

The authors would like to thank the members and participating institutes of the INTERFANT-99 study for generously providing leukemic samples.

Members of the INTERFANT-99 study are as follows: M. Campbell (Programa Infantil Nacional de Drogas Atineoplasicas (PINDA)), M. Felice (Argentina), A. Ferster (Children's Leukemia Group (CLCG)), I. Hann and A.Vora (UK Children's Cancer Study Group (UKCCSG)), L. Hovi (Nordic Society of Paediatric Haematology and Oncology (NOPHO)), G. Janka-Schaub (Cooperative Study Group for Treatment of ALL (COALL)), C.K. Li (Hong Kong), G. Mann (Berlin-Frankfurt-Munster Group-Austria (BFM-A)), T. LeBlanc (French ALL Group (FRALLE)), R. Pieters (Dutch Childhood Oncology Group (DCOG)), G. de Rossi and A. Biondi (Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)), J. Rubnitz (St Jude Children's Research Hospital (SJCRH)), M. Schrappe (Berlin-Frankfurt-Munster Group-Germany (BFM-G)), L. Silverman (Dana-Farber Cancer Institute (DFCI)), J.Stary (Czech Paediatric Haematology (CPH)), R. Suppiah (Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG)), T. Szczepanski (Polish Paediatric Leukemia and Lymphoma Study Group (PPLLSG)), and M. Valsecchi and P. de Lorenzo (Trial Operating Center (CORS)).